HR+/HER2- breast cancer readers: press release previews a peer-reviewed study validating a genomic assay to help guide chemotherapy selection.
Key Takeaways
- About 16% of HR+/HER2-negative tumors showed low endocrine activity
- Patients with low endocrine activity had improved distant recurrence-free outcomes with weekly paclitaxel
- Analysis validated prior results across randomized trials and predicts taxane chemotherapy benefit